In this pre-planned study, the primary endpoint was the effect of the anastrozole on all breast cancers, including ductal carcinoma in situ via a reduction of unbound oestradiol, as assessed by the oestradiol/SHBG (E2/SHBG) ratio. The gene discussed is SHBG; the disease is ductal breast carcinoma in situ.